Eli Lilly's Market Share Declines Amid Generic Weight-Loss Drug Surge in India
Eli Lilly has experienced a decline in its market share in India for GLP-1 weight-loss drugs, as generic versions flood the market following the expiration of the semaglutide patent. While Eli Lilly's market share fell from 61% to 56%, Novo Nordisk maintained its position at 25%. The introduction of cheaper generic semaglutide drugs has shifted consumer preferences, impacting Eli Lilly's sales of its more expensive tirzepatide-based brands. The Indian market, known for its robust generic drug industry, is seeing increased competition as local companies launch affordable alternatives. 
